Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Blood Cancer J. 2018 Jun 11;8(6):55. doi: 10.1038/s41408-018-0081-8.

Amer M Zeidan^{1

2}, Maximilian Stahl^{3

4}, Michelle DeVeaux⁵, Smith Giri^{3

4}, Scott Huntington^{3

4}, Nikolai Podoltsev^{3

4}, Rong Wang^{4

6}, Xiaomei Ma^{4

6}, Amy J Davidoff^{4

7}, Steven D Gore^{3

4}

¹ Yale University and Yale Cancer Center, New Haven, CT, USA. amer.zeidan@yale.edu.
² Yale Cancer Outcomes Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT, USA. amer.zeidan@yale.edu.
³ Yale University and Yale Cancer Center, New Haven, CT, USA.
⁴ Yale Cancer Outcomes Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT, USA.
⁵ Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
⁶ Department of Chronic Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.
⁷ Department of Health Policy and Management, School of Public Health, Yale University, New Haven, CT, USA.

No abstract available

Publication types